Market Access

Webinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

Heparin is a critical drug that is highly dependent on the global supply chain and is derived from a highly complex process.

Demand for semaglutide and other GLP-1s is expected to grow exponentially over the next 3–5 years.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The argument for weighing clinical points more heavily in the access equation.

A seminar shares key observations and learnings from the first round of direct price negotiations.

Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare coverage decisions.

Four tips for midsized companies when entering new global markets.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

A look at the current landscape and how young companies can set the stage for product launch.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.

Demonstrating clinical benefit is the ultimate gateway to smoother patient access.

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to take effect in 2027.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Identifying the inflators and deflators, and the role all stakeholders play.

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.